Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05168202 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05168202 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 56 participants.
The verdict
NCT05168202, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 alone and in combination with antineoplastic agents in participants with relapsed or refractory acute myeloid leukemia and relapsed or refractory and treatment-naive higher risk melodysplastic syndromes.
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG CC-95251
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2024-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05168202
The ClinicalTrials.gov registry entry for NCT05168202 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT05168202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05168202 about?
NCT05168202 is a clinical study titled "A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes". The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 alone and in combination with antineoplastic agents in participants with relapsed or refractory acute myeloid leukemia and relapsed or refractory and treatment-naive higher risk melodyspl...
What is the current status of trial NCT05168202?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-01-19. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT05168202?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), CC-95251 (DRUG).
Who is sponsoring clinical trial NCT05168202?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.